AGF

AGF Biotherapeutics is a pre-clinical stage biotechnology company focused on developing next-generation biologics for the treatment of retinal diseases. The company leverages its proprietary protein engineering platform to create multi-functional fusion proteins designed to overcome the limitations of current anti-VEGF therapies. Their lead programs target both VEGF and Angiopoietin-2 pathways to provide superior efficacy and durability in patients with neovascular age-related macular degeneration and diabetic macular edema. By optimizing molecular architecture, AGF aims to reduce the treatment burden for patients requiring frequent intravitreal injections.